In this video module, learn from experts about special considerations when selecting ARV medications during pregnancy including efficacy, pharmacokinetic and safety data.
Listen to experts converse about the latest data on weight gain and cardiometabolic toxicities with antiretroviral medications.
Learn about ART safety in aging PWH and approaches to deprescribing ARV and non-ARV medications during this clinical conversation between experts.
In this microlearning module, expert faculty share their approach to managing ART safety and tolerability in transgender individuals.
If you had told me 25 years ago that we would be obsessed with weight gain, I would have thought you were crazy. Yet here I am in clinic trying to decide what to do with possible ARV medication–related weight gain.
Two-drug ART continues to be a nice simplification strategy for people with HIV. Read my commentary on recent data presented at the Fall 2022 Conferences highlighting safety and tolerability of 2-drug regimens.
Hear updates about ART safety and tolerability highlighting special populations such as those with cardiometabolic toxicities and aging PWH from summer 2022, including select studies from the AIDS 2022 meeting.
In this video module, get updates on ART safety and tolerability, including select studies from the IDWeek and HIV Glasgow 2022 meetings.
Listen to expert insights from Dr. Jean Rene Anderson and Dr. William Short on their approach to optimizing HIV treatments during pregnancy.
Listen as Priscilla Y. Hsue, MD, and Jens D. Lundgren MD, DMSc, share their insights on applying the latest safety and tolerability data of HIV treatments in patients with cardiometabolic toxicities.
Hear from experts about their approach to caring for older patients with HIV, including deprescribing ARV and non-ARV medications to address polypharmacy and other geriatric syndromes.
Listen as 2 experts discuss approaches to ART safety and tolerability in transgender individuals, including clinically relevant drug interactions and additional considerations such as gender-affirming care.
Hear from expert faculty as they answer questions and discuss key considerations when evaluating potential ARV-related toxicities in special populations, including aging patients and populations with cardiometabolic toxicities.
This slideset provides an overview of the latest data on ART safety and tolerability, emphasizing unique populations such as pregnant women, aging patients, populations with cardiometabolic toxicities, and transgender persons.